From FDA labels and ClinicalTrials.gov

Do GLP-1s help Parkinson's?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists Parkinson's disease as an approved use, so prescribing one for it would be off-label. Exenatide-PD3 (Exenatide): Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment. Lancet, 2025 (pubmed.ncbi.nlm.nih.gov/39919773). ClinicalTrials.gov lists 9 trials of these medicines on it: 1 with posted results and 0 recruiting now.

Read from the registry and PubMed every day. The newest update here is May 6, 2026.

Published results

What the largest trials on Parkinson's disease found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Exenatide-PD3

Exenatide · 194 people · No clear benefit · Placebo-controlled randomized trial

Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment.

Lancet, 2025 (pubmed.ncbi.nlm.nih.gov/39919773)

The registry

Trials on Parkinson's disease, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Exenatide700
Liraglutide110
Semaglutide100
Posted results

What trials on Parkinson's disease reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT02953665Safety and Efficacy of Liraglutide in Parkinson's DiseaseLiraglutidePhase 263Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period (units on a scale), From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks). Full Analysis Set (Liraglutide-treated Subjects): -2.3; Full Analysis Set (Placebo-treated Subjects): -5.0.
From PubMed

Newest papers on GLP-1s and Parkinson's disease

  • Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/41880197)

    Meta-analysis · Brain Behav · Apr 1, 2026 · Raza H et al. · cited by 1

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

GLP-1s and Parkinson's disease: common questions

What did the largest trial on Parkinson's disease find?

Exenatide-PD3 (Exenatide, 194 people): Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment.

Is any GLP-1 FDA approved for Parkinson's disease?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for Parkinson's disease?

Exenatide, with 7 registered trials on it, then Liraglutide and Semaglutide with 1 each. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for Parkinson's disease?

None is recruiting on ClinicalTrials.gov now.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.